Positive CHMP approval for self-administered burosumab (Crysvita) for treatment of hypophosphatemia

Currently, burosumab subcutaneous injection requires administration by a healthcare professional (HCP). In this new draft approval, patients on a stable dose can be considered for self-administration. The first self-administered dose would need to be supervised by a HCP.

Source:

PharmaTimes